He was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc. – a clinical-stage oncology company based in Waltham, MA., which focused on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. During his time at Cerulean, the company completed a successful IPO (NASDAQ:CERU) in April 2014, and its clinical group, while increasing in size from one to 12 employees (including three oncologist MDs), launched eight clinical trials and brought its second experimental drug into the clinic.
Prior to being appointed to Cerulean in 2011, Edward served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc. – a publicly-traded cancer-focused biotechnology company located in Woburn, MA., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). He also served there as a clinical development liaison with external development partners, and helped plan and execute a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Edward was Medical Director at GPC Biotech in Princeton, New Jersey, where he helped oversee multiple global clinical development studies.
A pediatric hematologist-oncologist by training, Edward is a graduate of Harvard and New York Universities. He completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles, and the Memorial Sloan-Kettering Cancer Center (N.Y.). Edward completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for HIV Research in Gaborone, Botswana (1999-2000) and he is a recipient of Young Investigators awards from the American Society of Hematology and the American Heart Association.
Edward has presented at numerous international conferences and is an author on more than 50 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund’s $1.25 Million BioAccelerate NYC Prize for biomedical research. Additionally, in 2011, he was appointed to the scientific advisory board of the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative.
Edward lives near Boston, Massachusetts, where he serves as an instructor at Harvard Medical School’s Therapeutics Graduate Program and a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.Back